IP Library › Patent Application 16751850
Patent Application
App. No. 16/751,850

PHTHALOCYANINE PROBES AND USES THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/751,850
Abstract

The present invention relates to compositions and methods for destroying target cells in a patient using photodynamic therapy. In particular, the present invention provides a photosensitizing agent based on a small molecular weight (<50 kDa) protein or peptide or a small molecule that is conjugated to a phthalocyanine dye, such as IRDye® 700DX.

Claims (13)

1 . A therapeutically effective composition comprising IRDye700DX conjugated to a probe, which specifically binds to a cancer cell, wherein the probe has a molecular weight of less than about 10 kDa and is a member selected from the group consisting of a ligand, a peptide and a small molecule.

2 . The composition of claim 1 , wherein the probe is a ligand.

3 . The composition of claim 1 , wherein the probe is a peptide.

4 . The composition of claim 1 , wherein the probe is a small molecule.

5 . The composition of claim 2 , wherein the ligand is EGF.

6 . The composition of claim 3 , wherein the peptide is selected from the group consisting of YC-27, cRGDfK, vasoactive intestinal peptide, gastrin-releasing peptide, neurotensin, AH111585, FPPRGD2, PK11195, SPARC, bombesin, neurotensin, substance P, somatostatin, cholecystokinin, glucagon-like peptide-1, neuropeptide Y, octreotide, DOTA-TOC, DOTA-TATE, exendin-4, analogs thereof, derivatives thereof, and combinations thereof.

7 . The composition of claim 3 , wherein the peptide is selected from the group consisting of soricidin, SOR-13 and SOR-C27.

8 . The composition of claim 3 , wherein the small molecule is selected from the group consisting of a VEGFR inhibitor, a TNFR1 inhibitor, a growth factor receptor inhibitor and combinations thereof.

9 . The composition of claim 4 , wherein the small molecule VEGFR inhibitor is selected from the group consisting of pazopanib, semaxanib, axitinib, cabozantinib, aflibercept, brivanib, tivozanib, ramucirumab, motesanib, vatalanib, cediranib, and combinations thereof.

10 . The composition of claim 1 , wherein the probe is a radionuclide.

11 . The composition of claim 10 , wherein the probe is a member selected from the group consisting of DTPA-octreotide, [Gluc-Lys]-TOCA, galacto-RGD, AH111585, RGD-K5, FPPRGD2, RP-527, BZH 3 , [DTPA-Lys 40 ]-Exendin-4, and NT-X1.

12 . The composition of claim 1 , wherein the probe is conjugated to a fluorophore.

13 . The composition of claim 3 , wherein the peptide is chlorotoxin.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2021
From: LI-COR, INC.
To: RAKUTEN MEDICAL, INC.
Reel/Frame 055238/0885 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2020
From: KOVAR, JOY L.
To: LI-COR, INC.
Reel/Frame 051612/0591 →